FDA Cites Stephen J. Fallon, Ph.D. in 2026-08-27 Warning Letter — Bioresearch Monitoring Program/Institutional Review Board (IRB)
Letter issued · posted to fda.gov .
Subject as published: Bioresearch Monitoring Program/Institutional Review Board (IRB)
TL;DR
Here's the summary: The FDA Center for Biologics Evaluation and Research (CBER) issued a warning letter to Stephen J. Fallon, Ph.D. on August 27, 2026 (Reference #CBER-26-728673) citing violations observed during a June 2-13, 2025 inspection of his clinical study site conducting Protocol CLS-003, an INSTI® HIV Self-Test evaluation study. The violations include: failing to obtain and document legally effective informed consent per 21 CFR Parts 50 and 812 (35 of 42 informed consent forms lacked subject-recorded dates; subjects did not consistently receive signed consent copies); implementing changes to the informed consent form without IRB approval regarding compensation terms; and failing to ensure adequate study oversight and protocol adherence per the sponsor agreement and investigational plan.
Argus analysis
# FDA Warning Letter Analysis: Stephen J. Fallon, Ph.D.
**Company and Findings**
The FDA's Center for Biologics Evaluation and Research (CBER) issued a Warning Letter on August 27, 2026, to Stephen J. Fallon, Ph.D., regarding his role as clinical investigator for Protocol CLS-003, a study evaluating the INSTI® HIV Self-Test. An FDA inspection conducted June 2–13, 2025, identified multiple violations related to human subject protection and study conduct. The inspection occurred under the Bioresearch Monitoring (BIMO) Program, which oversees the integrity of clinical research involving investigational products. Dr. Fallon did not respond to the initial Form FDA 483 observations, preventing the agency from reviewing his explanations or corrective action plans.
**Regulatory Citations and Their Significance**
The violations cited span 21 CFR Part 50 (informed consent regulations) and Part 812 (investigational device requirements). Specifically, 21 CFR 50.27(a) and 812.100 violations involved failures to obtain legally effective informed consent—35 of 42 consent forms lacked subject-recorded dates, and study coordinators did not consistently provide subjects copies of signed forms. Additional violations included implementing ICF modifications without IRB approval (21 CFR 812.110(b)), failing to conduct the study per protocol and investigator agreement, and maintaining inadequate records including missing device lot numbers, inconsistent staff initials, and white-out corrections (21 CFR 812.140). These provisions form the regulatory foundation ensuring subject welfare and data integrity in clinical investigations.
**Timeline and Industry Implications**
Dr. Fallon was required to submit a written response addressing the violations. Peer compliance officers should monitor for follow-up enforcement actions, including potential clinical hold decisions or debarment proceedings if corrective measures are deemed insufficient. The pattern of documentation deficiencies and protocol deviations suggests systemic oversight gaps—investigators in biologics research should evaluate their delegation logs, ICF procedures, and device accountability systems accordingly.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Stephen J. Fallon, Ph.D. MARCS-CMS 728673 — August 27, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Electronic Email Reference #: CBER-26-728673 Product: Biologics Recipient: Stephen J. Fallon, Ph.D. 1401 North East 26th Street Wilton Manors , FL 33305 United States sfallon@latinosalud.org Issuing Office: Center for Biologics Evaluation and Research (CBER) United States WARNING LETTER CBER-26-728673 August 27, 2026 Dear Dr. Fallon: This Warning Letter informs you of objectionable conditions observed during a U.S. Food and Drug Administration (FDA) inspection conducted at your clinical study site between June 2, 2025, and June 13, 2025. The FDA Investigators met with you during the inspection to review your conduct and oversight as a clinical investigator of the clinical study entitled, “ A study to evaluate the performance, usability, and result interpretation of INSTI® HIV Self-Test when performed by observed intended users in the US ” (Protocol CLS-003). FDA conducted this inspection under the Bioresearch Monitoring (BIMO) Program, which includes inspections designed to review the conduct of research involving investigational products and to help ensure that the rights, safety, and welfare of human subjects are being protected. At the conclusion of the inspection, a Form FDA 483, Inspectional Observations, was issued and discussed with you. We reviewed the Establishment Inspection Report (EIR), documents accompanying that report and the Form FDA 483 issued to you. Because you did not provide a response to the list of observations from your inspection, we were unable to evaluate your perspective on the findings, your explanations for the deficiencies, or your commitment to implementing further measures to prevent similar problems in the future, along with a clear timeline to achieve any planned implementation. Based on our review of the Establishment Inspection Report (EIR), documents accompanying that report, and the Form FDA 483, you violated regulations governing the proper conduct of clinical studies involving investigational products, including regulations published in Title 21 of the Code of Federal Regulations (CFR), part 812 [21 CFR 812] and 50 [21 CFR 50] (available at Code of Federal Regulations Title 21 ). The applicable provisions of the CFR are cited for each violation listed below. The violations include but are not limited to the following: 1. You failed to properly obtain and document legally effective informed consent in accordance with the provisions of 21 CFR Part 50.27(a) and 21 CFR 812.100. You did not ensure that informed consents were signed and dated by the subject or the subject’s legally authorized representative at the time of consent, and you did not ensure a copy of the consent was given to the person signing the informed consent form (ICF). a. Of the 42 ICFs signed by subjects, 35 showed that the study subjects did not personally record the effective c…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was Stephen J. Fallon, Ph.D. cited for?
- The FDA Warning Letter to Stephen J. Fallon, Ph.D. (issuing office: Center for Biologics Evaluation and Research (CBER)) cites: Bioresearch Monitoring Program/Institutional Review Board (IRB). Classification: Warning Letter.
- When did FDA issue the warning letter to Stephen J. Fallon, Ph.D.?
- FDA issued the letter (MARCS-CMS 728673) on 2026-08-27 and posted it publicly on fda.gov on 2026-09-08.
- Is the FDA warning letter to Stephen J. Fallon, Ph.D. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stephen-j-fallon-phd-728673-08272026.
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Stephen J. Fallon, Ph.D. in 2026-08-27 Warning Letter — Bioresearch Monitoring Program/Institutional Review Board (IRB). Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-stephen-j-fallon-ph-d-2026-08-27-warning-letter
"FDA Cites Stephen J. Fallon, Ph.D. in 2026-08-27 Warning Letter — Bioresearch Monitoring Program/Institutional Review Board (IRB)." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-stephen-j-fallon-ph-d-2026-08-27-warning-letter.
Argus HQ Research. "FDA Cites Stephen J. Fallon, Ph.D. in 2026-08-27 Warning Letter — Bioresearch Monitoring Program/Institutional Review Board (IRB)." Digital Empire Holdings LLC. Accessed September 9, 2026. https://argushq.ai/fda/warning-letter/fda-wl-stephen-j-fallon-ph-d-2026-08-27-warning-letter.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_stephen_j_fallon_ph_d_2026_08_27_warning_letter_2026,
title = {FDA Cites Stephen J. Fallon, Ph.D. in 2026-08-27 Warning Letter — Bioresearch Monitoring Program/Institutional Review Board (IRB)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-stephen-j-fallon-ph-d-2026-08-27-warning-letter},
note = {Accessed: September 9, 2026}
}